Chronic pain has a severe impact not only on individual sufferers’ physical and mental health but also on national economies . In the USA almost 20% of adults suffer from chronic pain (2016) with an estimated annual cost of $560 billion in direct medical costs, lost productivity, and disability programs.
Existing chronic pain drugs are only partly effective and only for some patients and they are associated with significant side effects. PharmNovo’s mission is to develop safe and effective medicines for chronic pain treatment.
Our team has taken our lead candidate PN6047 successfully through preclinical studies and it is now ready for first in man clinical studies. This is a great achievement for a small Biopharma company. Today, I am totally convinced that we can deliver safe and effective medicine for the treatment of chronic, neuropathic pain.
Medicon Village AB
SE-223 81 Lund, Sweden